Vident Investment Advisory, LLC Precision Biosciences Inc Transaction History

Vident Investment Advisory, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.15 - $3.34 $20,445 - $59,381	-17,779 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $11,703 - $30,683	-3,954 Reduced 18.19%	17,779 $55,000
Q4 2021 Feb 14, 2022	BUY	$7.4 - $11.66 $160,824 - $253,406	21,733 New	21,733 $161,000
Q3 2021 Nov 12, 2021	SELL	$9.18 - $14.15 $181,167 - $279,250	-19,735 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.07 - $12.52 $159,261 - $247,082	19,735 New	19,735 $247,000
Q2 2020 Jul 17, 2020	SELL	$4.66 - $8.7 $698,277 - $1.3 Million	-149,845 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$5.05 - $15.01 $47,252 - $140,448	-9,357 Reduced 5.88%	149,845 $904,000
Q4 2019 Feb 11, 2020	BUY	$6.32 - $19.66 $291,307 - $906,188	46,093 Added 40.75%	159,202 $2.21 Million
Q3 2019 Nov 13, 2019	SELL	$8.03 - $14.82 $30,851 - $56,938	-3,842 Reduced 3.29%	113,109 $949,000
Q2 2019 Aug 12, 2019	BUY	$11.88 - $16.94 $1.39 Million - $1.98 Million	116,951 New	116,951 $1.55 Million

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $526M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.